ArticleScience immunology2022
SARS-CoV-2 epitope-specific CD4
Open access · greenAbstract read
In one paragraph
Article in Science immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Immunogenicity and safety of the booster COVID-19 vaccine among people with HIV: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost study.Frontiers in immunology · 2025Trial
- Safety and efficacy of dendritic cell vaccine for COVID-19 prevention after 1-Year follow-up: phase I and II clinical trial final result.Frontiers in immunology · 2023Trial
- Serial vaccination expands and refines human CD4bioRxiv : the preprint server for biology · 2026Article
- The genetic basis of the immune response to SARS-CoV-2 infection and vaccination in the Italian municipality of Vo'.Frontiers in immunology · 2026Article
- Establishing long-lasting vaccine immunity: insights from mRNA and adjuvanted protein platforms.NPJ vaccines · 2025Review
- Long-persisting SARS-CoV-2 spike-specific CD4Nature communications · 2025Article
- Infant CD4 T-Cell Response to SARS-CoV-2 mRNA Vaccination Is Restricted in Cytokine Production and Modified by Vaccine Manufacturer.Open forum infectious diseases · 2025Article
- SARS-CoV-2 Infection in Children: Revisiting Host-Virus Interactions Through Post-Infection Immune Profiling.Pathogens (Basel, Switzerland) · 2025Article
- Moloney Murine Leukemia Virus-like Nanoparticles Pseudo-Typed with SARS-CoV-2 RBD for Vaccination Against COVID-19.International journal of molecular sciences · 2025Article
- Serum anti-nucleocapsid antibody correlates of protection from SARS-CoV-2 re-infection regardless of symptoms or immune history.Communications medicine · 2025Article
- mRNA vaccine-induced SARS-CoV-2 spike-specific IFN-γ and IL-2 T-cell responses are predictive of serological neutralization and are transiently enhanced by pre-existing cross-reactive immunity.Journal of virology · 2025Article
- Polyfunctional T peripheral helper cells are associated with the magnitude and durability of antibody responses after COVID-19.Clinical & translational immunology · 2025Article
- Patterns of restricted TCR usage following SARS-CoV-2 vaccination and severe disease.Frontiers in immunology · 2025Article
- Uncovering cell-type-specific immunomodulatory variants and molecular phenotypes in COVID-19 using structurally resolved protein networks.Cell reports · 2024Article
- Correlates of Nucleocapsid Antibodies and a Combination of Spike and Nucleocapsid Antibodies Against Protection of SARS-CoV-2 Infection During the Omicron XBB.1.16/EG.5-Predominant Wave.Open forum infectious diseases · 2024Article
- Evaluation of an RBD-nucleocapsid fusion protein as a booster candidate for COVID-19 vaccine.iScience · 2024Article
- Lack of memory recall in human CD4 T cells elicited by the first encounter with SARS-CoV-2.iScience · 2024Article
- SARS-CoV-2 inflammation durably imprints memory CD4 T cells.Science immunology · 2024Article
- Analysis of Cell Immunity for Children Infected with SARS-CoV-2 and Those Vaccinated against SARS-CoV-2 Using T-SPOTMicroorganisms · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Ryan W NelsonCenter for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-2327-9481
Yuezhou ChenDepartment of Medicine, Division of Allergy and Clinical Immunology and Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-3453-1988
Olivia L VeneziaCenter for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Richard M MajerusQueens University of Charlotte, Charlotte, NC, USA.
Daniel S ShinCenter for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-5873-1920
MGH COVID-19 Collection & Processing Team
Mary N CarringtonRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.ORCID 0000-0002-2692-2180
Xu G YuInfectious Disease Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-8295-884X
Duane R WesemannDepartment of Medicine, Division of Allergy and Clinical Immunology and Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-6690-944X
James J MoonCenter for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-8246-931X
Andrew D LusterCenter for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-9679-7912
Brigham and Women's Hospital · USHarvard University · USBoston Children's Hospital · USQueens University of Charlotte · USRagon Institute of MGH, MIT and Harvard · US
Funding
The Harvard Clinical and Translational Science CenterUL1TR002541 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2018 to 2022
$93.0MPilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Ramnik J Xavier · 1991 to 2026
$35.3MTechnology and Computational CoreP01AI165072 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI WESEMANN, DUANE R. · 2021 to 2023
$19.6MMOLECULAR BASIS OF ALLERGIC AND IMMUNOLOGIC DISEASET32AI007512 · NIAID · CHILDREN'S HOSPITAL BOSTON · PI Janet Chou, Peter A Nigrovic · 1996 to 2026
$13.1MIMMUNOLOGIC BASIS OF RESISTANCE AND HYPERSENSITIVITYT32AI007306 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Nora Amanda Barrett, Joshua A Boyce · 1985 to 2026
$12.2MLung-Resident Memory Th2 cells in Asthma - New Therapeutic TargetsR01AI040618 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LUSTER, ANDREW D · 1997 to 2022
$5.6MChemokines and Th2 Cell Trafficking in AsthmaR37AI040618 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LUSTER, ANDREW D · 2008 to 2017
$4.0MAntibody Durability DynamicsR01AI170715 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Duane R. Wesemann · 2022 to 2026
$3.4MElucidating Germinal Center-Mediated Antibody EvolutionR01AI139538 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI WESEMANN, DUANE R. · 2019 to 2022
$2.4MHost genetic resistance to COVID-19ZIABC011949 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CARRINGTON, MARY N. · 2020 to 2025
$997kNCATS NIH HHS UL1 TR002541NCI NIH HHS HHSN261200800001ENIAID NIH HHS P01 AI165072NIAID NIH HHS R01 AI040618NIAID NIH HHS R01 AI139538NIAID NIH HHS R01 AI170715NIAID NIH HHS R37 AI040618NIAID NIH HHS T32 AI007306NIAID NIH HHS T32 AI007512NIDDK NIH HHS P30 DK043351
Abstract
CD4
Indexed as
COVID-19SARS-CoV-2CD4-Positive T-LymphocytesEpitopesHumansLongitudinal StudiesMemory T CellsSeverity of Illness IndexEpitopes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.